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ETble cell products. On that basis, we believe the approach
hat we have chosen to be effective.
iscussion
ichard D. Weisel (Toronto, Canada). I greatly appreciate the
xcellent presentation, and I thank Drs Steinhoff and Stamm for
ending me the manuscript in advance.
This study is important for cardiac surgeons because it echoes
he information I presented last year suggesting that surgeons not
nly need to bypass coronary arteries, fix ventricles, and repair
alves but also need to change the response of the heart to our
nterventions. Surgeons should introduce biologic interventions
henever they perform mechanical interventions. Your study dem-
nstrates that biologic interventions can have profound effects of
he response of the heart to our mechanical interventions. Unfor-
unately, you have not identified the mechanisms responsible for
he benefit, and we therefore may have difficulty integrating this
pproach into our surgical practice.
When we originally implanted cells into the heart, we thought
e were producing new heart cells. Subsequent studies have
etermined that none of the cells implanted into the heart trans-
ifferentiated into new heart cells. The mechanism responsible for
he improved function seen after the implantation of a variety of
ell types has thus not been elucidated. How does cellular trans-
lantation work? We have previously demonstrated that cellular
ransplantation induces angiogenesis and matrix remodeling, as
ell as recruiting endogenous stem cells from the heart and the
one marrow to the heart. If these are the mechanisms responsible
or the improved function, then perhaps we need to augment those
ffects with any surgical interventions on the heart. So my first
uestion for you is as follows: What is the mechanism responsible
or the functional benefit, and should you augment your cells with
enes or proteins to increase the benefit of cellular transplantation?
o you believe that your cells will transdifferentiate into cardio-
yocytes?
I also had some concerns with your study. You had difficulty
ith the randomization. You were unable to complete the study
ccording to your original trial design because of the unavailability
f the room to perform the bone marrow biopsy. I am therefore
oncerned that you may have biased the randomization.
In your article, you report a significant difference between the
wo groups in end-systolic volume. I was concerned that the
ontrol group, the CABG alone group, had larger hearts before the
peration and that this could not be improved with any type of
herapy. Only 6 of your control patients had improvement postop-
ratively and 14 did not, which is not what we would anticipate
fter CABG. In addition, you did not use the Canadian laser in
our control group. The Canadian laser is the insertion of a needle
nto the heart, which previous investigators have demonstrated to
ncrease angiogenesis. The needle injection itself may have im-
roved the functional outcome, and this procedure was only used
n the cell transplant group, not the control group. I suggest that
ou use needle injection in your proposed phase III trial.
Finally, I was concerned about the randomization, because only
additional patients showed an improvement in LVEF in thereatment versus the control groups. The LVEF increased in 8 s
The Journal of Thoracicreated patients and 6 control patients. This difference was small
ut statistically significant. The difficulty you had with random-
zation thus could have influenced the outcomes.
In summary, I think that this is an important study, and it
ertainly will advance the field. Cardiac surgeons should go on to
he next phase to develop a new treatment to restore cardiac
unction in our patients undergoing CABG. We should establish
he mechanisms responsible for the improved function, however,
ut then augment those effects by adding genes or proteins to the
ells implanted into the infarcted myocardium. Biologic interven-
ions may be as important as mechanical treatments to restore our
atients to full activity.
Dr. Steinhoff. Thank you, Dr. Weisel. The introduction of such
method has several phases, and this first phase I and II study of
D133 intramyocardial stem cell transplantation is testing
afety, and biological effects. Of course, the last is a difficult
ption with the diagnostic methods we have available. To unravel
he underlying mechanisms there has to be a high correspondence
etween experimental models and clinical studies. I think it is
ifficult, at present, to exactly understand the sequence of cellular
eactions that lead to cardiac regenerative processes.
We just had the basic science lecture about apoptosis, and
poptosis is also probably an important feature of exchange of
ells necessary for tissue regeneration. So I think the addition of
nti-apoptotic substances such as genes may be important; we have
one research in anti-apoptotic gene transfer with stem cells and
ound a higher therapeutic effect in experimental models. Or
roteins may be added. There are a number of candidate proteins
hat can improve stem cell function in the heart, which may lead
he next clinical introductory phase. However, we have to learn
tep-by-step how stem cells can be used in cardiac therapy, what
herapeutic effects they have, whether they are safe, whether or not
hey have side effects, how we can apply them, and in what disease
ondition.
In our study, we tried to find such a clinical therapeutic window
reating chronic ischemia with intramyocardial injection of autol-
gous CD133 stem cells as an adjunct to a conventional CABG
rocedure. Of course, we are well aware of the weak points of our
ata. As you mentioned, we do not have a sham needle injection in
he control group. We also had to overcome logistic problems in
he prospective randomization of patients considering the bone
arrow stem cell harvest and cell isolation methods. As compared
o controls, however, we have seen in 35 patients treated with stem
ells a consistent improvement in cardiac function—as great as
7% and with a mean of 10%—and I think that is really impres-
ive. The lack of side effects is giving us confidence to go to the
ext clinical phase III study and to extend the experience. There
re, of course, continuing improvements in isolation methods and
onditioning of cells.
With respect to your mention of the control group, I agree that
ham needle injection would be needed, and a next controlled
tudy should include that. Also, a double-blinded study, as here it
s only a single-blinded study, will be necessary to give the hard
ata needed for clinical introduction. Of course, this will take some
ime, but I am positive that we have good prospects for cardiac
tem cell therapy in chronic ischemic heart disease.
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